NTLA-3001 / Intellia Therap - LARVOL DELTA

AATD: NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Intellia Therapeutics | N=30 ➔ 0 | Trial completion date: May 2030 ➔ Jan 2025 | Recruiting ➔ Withdrawn | Trial primary completion date: Mar 2030 ➔ Jan 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases

AATD: NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Intellia Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases

AATD: A Phase 1/2 Study of NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Intellia Therapeutics

New P1/2 trial • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire) - "Upcoming Milestones: The Company has set forth the following expected milestones for pipeline progression: NTLA-2002 for HAE: Present additional clinical data from the ongoing first-in-human study of NTLA-2002 in 2023. Complete enrollment in the Phase 2 portion of the Phase 1/2 study in 2H 2023; AATD Franchise: Submit an IND or IND-equivalent application for NTLA-3001 for AATD-associated lung disease in 2H 2023. Complete IND-enabling activities for NTLA-2003 for AATD-associated liver disease by year-end 2023."

IND • P1/2 data • Trial status • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hereditary Angioedema